Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of GELSECTAN® Administration on Covert Hepatic Encephalopathy (CHE) in Patients With Cirrhosis.

NCT05189834 is registered in ClinicalTrials.gov with Consorci Sanitari de l'Alt Penedès i Garraf as lead sponsor.

NCT NCT05189834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05189834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of GELSECTAN® Administration on Covert Hepatic Encephalopathy (CHE) in Patients With Cirrhosis.
Lead sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Phase
Not applicable
Overall status
Withdrawn
Start date
March 11, 2022
Completion date
July 30, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covert hepatic encephalopathy